SUMMARY Four young Chinese women took daily doses of an unidentified 'Indian' herbal tea as treatment for psoriasis. Three (one of whom died), developed ascites, hepatomegaly and biochemical abnormalities within 19-45 days. The fourth patient discontinued herbal tea after 21 days when she developed a skin rash. Two patients had portal hypertension, while all had liver histology showing features of veno-occlusive disease. Pyrrolizidine alkaloids were identified spectrophotometrically in the brewed tea, and in the chopped leaves of the herbal mixture; the mean dose in the tea prepared for consumption being 12 mg/day of alkaloid base and 18 mg/day of N-oxide. The mean cumulative dose of alkaloids (base + N-oxide) before onset of symptoms (three patients), was estimated to be 18 mg/kg. In the asymptomatic patient with histological liver disease only, the corresponding dose was 15 mg/kg. These cases thus provide some measure of pyrrolizidine alkaloid toxicity in adults.
an Indian, who had experienced remission of his psoriasis, ascribed to drinking the very same tea while on a recent visit to India. All five individuals were consulting the same dermatologist. Everyday, each patient put a pre-packed mixture of herbs into about 800 ml water, which was brought to the boil and reduced to half its original volume by simmering. After adding one teaspoonful each of a dark paste and a dark syrup to the brew, the liquid was consumed; half in the morning and half in the evening. The full recommended course of treatment was six months.
Pertinent personal and laboratory data from the four patients are summarised in the Table. Patients 1, 2, and 3 developed abdominal distension (hepatomegaly with ascites), 45, 30, and 19 days respectively, after starting to imbibe the tea, and after a further period of 16, 36, and 49 days, respectively, they were admitted to Queen Mary Hospital. With the onset of symptoms, patients 1 and 3 stopped consuming the tea and experienced clinical and biochemical remission. Patient 2 persisted in taking the tea for 16 days after the onset of symptoms, against medical advice, and continued 101 Table) , presumably reflects the short duration of the latter. Patient 2 who died, continued taking the tea for a further 16 days after the onset of symptoms and thus took a total dose of about 1380 mg over 46 days. Although the condition of the chopped leaves (source of toxic alkaloids), made definite botanical identification very difficult, an attempt was made to classify them based on surface processes and general anatomy.9 The leaves belonged to genera of the family of Compositae, but on balance it seemed unlikely that they were from any Senecio species.
Discussion
Hepatotoxic pyrrolizidine alkaloids occur in a large number of plants, notably in the Boraginaceae (genus Heliotropium), Leguminosae (genus Crotalaria) and Compositae (subdivision Senecioneae). 10 The occurrence of two cases of veno-occlusive disease in Northern China11 was associated with the use of the plant t'u-san-chi'i (Gynura segetum, family Compositae)12 in quantities of 36-45 g daily, as a medicinal tea. The species of poisonous plant taken by our patients though not identified precisely, also appeared to belong to the Compositae family. Of further relevance to the source of the herbs obtained by our patients, is a report by Gupta and others13 from New Delhi describing hepatic veno-occlusive disease occuring after unidentified herbal medicines were used in the treatment of a patient with ichthyosis and a patient with psoriasis.
Total pyrrolizidine alkaloid consumption producing infantile intoxication in Arizona has been estimated to be about 70-147 mg given over 14 days in a 6 month old baby who lived, and 66 mg given over four days in a 2 month old baby who died. Assuming that these infants weighed about 8 and 5 kg respectively, the corresponding dosage would have been about 9-18 and 13 mg/kg. In our series by comparison, the estimated cumulative doses before development of symptoms in patients 1, 2 and 3 were 26, 15 and 12 mg/kg respectively. Patient 4, who had asymptomatic hepatic veno-occlusive disease, consumed about 15 mg/kg. In patient 2 who died, the estimated cumulative dose up till the onset of symptoms was the same as that in patient 4 who was asymptomatic. Moreover, the total calculated dosage consumed by the fatal case was 23 mg/kg and compares with 26 mg/kg for patient 1 who survived.
Thus, though from a small number of cases, our results provide some data on the extent of alkaloid exposure liable to produce toxicity. They also suggest considerable individual variation in susceptibility among patients who were of the same sex and race, and nearly the same age. To our knowledge, this report is the first such quantitation of pyrrolizidine alkaloid hepatotoxicity in adults. 
